Co-administration of vaccination with DNA encoding T cell epitope on the Der p and BCG inhibited airway remodeling in a murine model of chronic asthma.
Therapeutic modalities of airway remodeling in asthma have proved to be unsuccessful regarding reversing the previously established chronic airway changes. Recently, the potential of plasmid DNA to inhibit the Th2 immune response has been demonstrated in animal models of asthma. Bacillus Calmette-Guerin (BCG) immunization also induced immunomodulation, which appeared to be reliant on the properties of the interferon-gamma that was produced. Mice were immunized with house dust mite extract (HDM). At the 3 week point, we injected BCG subcutaneously into mice on three successive weeks. One week after the BCG injection, we immunized mice with the DNA plasmid encoding for murine T-cell epitope on Dermatophagoide pteronyssinus 2 thrice weekly. At 9 weeks after immunization, we measured airway responsiveness. Twenty four hours later, we performed bronchoalveolar lavage and histological examinations. Co-administration of DNA vaccination and BCG resulted in a partial suppression of the overproduction of goblet cells and the thickness of the peribronchial smooth muscle in ongoing allergic responses. In the bronchoalveolar lavage fluid, the number of total cells and eosinophils was reduced, and regarding the change of cytokines, the concentration of IL-4 was also decreased, but interferon-gamma was increased in the co-administration group, opposed to the asthma group. These results suggest that co-administration of vaccination with the DNA encoding T-cell epitope and BCG are effective regarding ongoing allergic response and might constitute an ideal method for combating allergic disease in the future.
Kim
Chi Hong
CH
Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea.
Ahn
Joong Hyun
JH
Kim
Seung Joon
SJ
Lee
Sook-Young
SY
Kim
Young Kyoon
YK
Kim
Kwan Hyoung
KH
Moon
Hwa Sik
HS
Song
Jeong Sup
JS
Park
Sung Hak
SH
Kwon
Soon Seog
SS
D000818:Animals; D039741:Antigens, Dermatophagoides / Q000276:immunology*; D060829:Arthropod Proteins; D001249:Asthma / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D001500:BCG Vaccine / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005260:Female; D020397:Goblet Cells / Q000473:pathology; D006965:Hyperplasia; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007167:Immunotherapy / Q000379:methods; D018836:Inflammation Mediators / Q000378:metabolism; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D039981:Pyroglyphidae / Q000276:immunology*; D012129:Respiratory Function Tests; D019444:Vaccines, DNA / Q000276:immunology*
D039741:Antigens, Dermatophagoides; D060829:Arthropod Proteins; D001500:BCG Vaccine; D016207:Cytokines; C451163:Dermatophagoides pteronyssinus antigen p 2; D018984:Epitopes, T-Lymphocyte; D007074:Immunoglobulin G; D018836:Inflammation Mediators; D019444:Vaccines, DNA; D007073:Immunoglobulin E